Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
5 Small-Cap ETFs to Profit From the January Effect
by Sweta Killa
After registering double-digit annual growth, Wall Street is poised to gain from the historical trend of January Effect.
Best Growth Stocks to Buy for January 5th
by Zacks Equity Research
ABG, APO, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 5, 2022
AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug
by Zacks Equity Research
AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
The Zacks Analyst Blog Highlights: Meta Platforms, Inc., Bank of America Corporation, Mastercard Inc., Pfizer Inc. and Medtronic plc
by Zacks Equity Research
Meta Platforms, Inc., Bank of America Corporation and Mastercard Inc., Pfizer Inc. and Medtronic plc are highlighted in this analyst blog.
Top Stock Reports for Meta Platforms, Bank of America & Mastercard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (FB), Bank of America Corporation (BAC), and Mastercard Incorporated (MA).
Here's Why Momentum Investors Will Love Pfizer (PFE)
by Zacks Equity Research
Does Pfizer (PFE) have what it takes to be a top stock pick for momentum investors? Let's find out.
PFE vs. RHHBY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. RHHBY: Which Stock Is the Better Value Option?
Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.
New Strong Buy Stocks for January 4th
by Zacks Equity Research
ABG, CNTY, IIJIY, ORAN, and PFE have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2022.
Spero (SPRO) Application for UTI Drug Gets Priority Review
by Zacks Equity Research
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
Best Growth Stocks to Buy for January 4th
by Zacks Equity Research
ABG, PFE, and APO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 4, 2022
Company News for Jan 3, 2022
by Zacks Equity Research
Companies In The News Are: PFE, CTRA, AMD, XLNX, NVAX.
Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine
by Zacks Equity Research
Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.
Here's Why Pfizer (PFE) Appears Strongly Placed for 2022
by Kinjel Shah
While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver
J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron
by Zacks Equity Research
Johnson & Johnson's (JNJ) COVID booster vaccine demonstrates 85% effectiveness against COVID-related hospitalization in South Africa, with Omicron becoming the dominant variant.
Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group
by Zacks Equity Research
Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $57.58, moving -0.74% from the previous trading session.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
5 Sector ETFs That Crushed the Market in December
by Sweta Killa
With just a few trading sessions left to end December, the S&P 500 index has gained 4.8%. A few sector ETFs have outperformed.
Novavax (NVAX) COVID Jab Gets Nod for Emergency Use in India
by Zacks Equity Research
Novavax (NVAX) secures approval in India for emergency use of its COVID-19 vaccine.
Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
by Zacks Equity Research
Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.
Holiday Sales Boom: Retail ETFs to Buy At a Bargain
by Sweta Killa
Retail sales surged the most in nearly two decades this holiday season powered by soaring ecommerce sales as well as a rush to stores amid supply chain concerns, rising inflation and the raging new COVID-19 variant.
Stock Market News for Dec 27, 2021
by Zacks Equity Research
U.S. stocks closed higher for the third consecutive day on Thursday, with the S&P 500 hitting a record high ahead of a long Christmas holiday weekend as investors shed fears and felt more optimistic that the Omicron variant of the coronavirus won¿¿¿t affect global economy growth.
Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use
by Zacks Equity Research
Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.